Ciaran Murray Sells 2,677 Shares of Icon (NASDAQ:ICLR) Stock

Icon Plc (NASDAQ:ICLR) Director Ciaran Murray sold 2,677 shares of the firm’s stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $164.29, for a total value of $439,804.33. Following the sale, the director directly owned 20,452 shares of the company’s stock, valued at $3,360,059.08. This represents a 11.57% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Icon Price Performance

ICLR traded up $1.59 during trading on Wednesday, hitting $167.17. The company’s stock had a trading volume of 804,300 shares, compared to its average volume of 1,385,101. The company has a quick ratio of 0.95, a current ratio of 0.95 and a debt-to-equity ratio of 0.23. The stock has a market capitalization of $12.80 billion, a price-to-earnings ratio of 39.24, a price-to-earnings-growth ratio of 6.88 and a beta of 1.21. The firm’s 50 day moving average price is $161.47 and its two-hundred day moving average price is $134.31. Icon Plc has a 12 month low of $66.57 and a 12 month high of $203.91.

Icon (NASDAQ:ICLR) last announced its earnings results on Thursday, July 30th. The medical research company reported $2.56 EPS for the quarter, topping the consensus estimate of $2.55 by $0.01. Icon had a return on equity of 8.02% and a net margin of 3.99%.The company had revenue of $2.06 billion for the quarter, compared to analysts’ expectations of $2 billion. During the same quarter in the prior year, the business earned $3.26 earnings per share. The business’s revenue for the quarter was up 2.3% on a year-over-year basis. Sell-side analysts forecast that Icon Plc will post 9.57 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of ICLR. Geneos Wealth Management Inc. raised its stake in Icon by 11.5% in the second quarter. Geneos Wealth Management Inc. now owns 541 shares of the medical research company’s stock valued at $79,000 after buying an additional 56 shares during the period. Sanctuary Advisors LLC boosted its stake in shares of Icon by 1.1% during the 4th quarter. Sanctuary Advisors LLC now owns 4,932 shares of the medical research company’s stock worth $899,000 after acquiring an additional 56 shares during the period. GAMMA Investing LLC boosted its stake in shares of Icon by 21.4% during the 2nd quarter. GAMMA Investing LLC now owns 391 shares of the medical research company’s stock worth $68,000 after acquiring an additional 69 shares during the period. Janney Montgomery Scott LLC increased its holdings in shares of Icon by 0.4% during the 4th quarter. Janney Montgomery Scott LLC now owns 23,942 shares of the medical research company’s stock worth $4,363,000 after acquiring an additional 93 shares during the last quarter. Finally, Westpac Banking Corp raised its stake in Icon by 9.9% in the 4th quarter. Westpac Banking Corp now owns 1,146 shares of the medical research company’s stock valued at $209,000 after acquiring an additional 103 shares during the period. Institutional investors own 95.61% of the company’s stock.

Trending Headlines about Icon

Here are the key news stories impacting Icon this week:

• Positive Sentiment: Icon’s latest quarterly results modestly exceeded expectations: adjusted EPS was $2.56 versus the $2.55 consensus, while revenue reached $2.06 billion, above the $2.00 billion estimate and up 2.3% year over year. Analysts expect approximately $9.57 in full-year EPS, providing a fundamental support for the stock.
• Positive Sentiment: Recent analyst actions have generally been constructive. BMO Capital Markets raised its price target to $187 and Mizuho increased its target to $190, both maintaining outperform ratings. The consensus target is $170.40, modestly above the latest trading level, although the overall consensus rating remains “Hold.”
• Positive Sentiment: Short interest is reported at zero shares, indicating no measurable bearish short-selling pressure or potential forced-selling overhang.
• Neutral Sentiment: CEO Barry Balfe sold 382 shares worth about $62,675, while CFO Nigel Clerkin sold 2,267 shares worth approximately $372,445. Directors John Climax and Linda Grais each sold 841 shares at about $164.29. The filings state that all transactions were made to cover tax-withholding obligations tied to vested equity awards, reducing their usefulness as a signal of declining confidence. SEC insider transaction filing
• Negative Sentiment: Despite the revenue beat, quarterly EPS fell from $3.26 a year earlier, and Icon’s reported net margin was only 3.99%. The stock also carries a high valuation, with a price-to-earnings ratio near 39 and a PEG ratio of 6.88, leaving it sensitive to any slowdown in clinical-research demand or earnings growth.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on ICLR shares. TD Cowen upped their target price on shares of Icon from $164.00 to $197.00 and gave the stock a “buy” rating in a research report on Thursday, June 25th. JPMorgan Chase & Co. boosted their price objective on shares of Icon from $130.00 to $155.00 and gave the stock a “neutral” rating in a research report on Thursday, June 25th. Zacks Research raised Icon from a “strong sell” rating to a “hold” rating in a report on Tuesday, July 28th. Leerink Partners set a $145.00 price objective on Icon in a research report on Thursday, May 28th. Finally, Royal Bank Of Canada raised Icon from a “sector perform” rating to an “outperform” rating and lifted their target price for the company from $126.00 to $185.00 in a research note on Thursday, June 25th. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, seven have given a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Hold” and an average target price of $170.40.

About Icon

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.